United Therapeutics Corporation: shareholders and insiders

UTHRNASDAQHealthcare · Pharmaceutical Preparations

Price

$559.10

November 19, 2026Market cap $24.5B

What Ploutos Investor adds for United Therapeutics

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 17 fiscal years, from 2009
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • The filings show substantial debt that is not stated in a form we can read. The debt, net cash, enterprise value, the multiples built on it and the return on invested capital would leave that debt out, so we leave them out.

Insiders and their shares

Purchases and sales by officers and directors, from their own Form 4 filings.

Reading the newest filings from the SEC. This part fills in on its own in a few seconds.

Major holders (over 5%)

Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.

1 Holders over 5%Nov 4, 2026 Latest filing
  • Vanguard Capital Management
    Share of class5.19%
Fell to 5% or less (4)

Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.

  • Martine A. Rothblatt4.00%Nov 4, 202613G/A
  • Wellington Management Group LLP3.20%Aug 13, 202613G/A
  • The Vanguard Group0.00%Mar 27, 202613G/A
  • State Street4.90%Feb 5, 202513G

From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.

Well-known managers

Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.

Sep 30, 2026 quarter end
  • Renaissance Technologies
    In the quarter-1.9%
  • Bridgewater (Dalio)
    In the quarter+13%
  • Citadel Advisors (Griffin)
    In the quarter+205%
  • Point72 (Cohen)
    In the quarter-12%
  • Millennium Mgmt (Englander)
    In the quarter-27%
  • AQR Capital
    In the quarter-22%

From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).

Short sales in daily trading

How much of the shares that changed hands were short sales, in the off-exchange trades brokers report each day.

46.7% the last 14 sessions-18.7 pts vs the 14 before

In the last 14 sessions, 46.7% of the shares in the reported trades were short sales, against 65.4% in the 14 before.

Last 14 sessionsNov 2, 2026 – Nov 19, 2026
46.7%
The 14 beforeOct 13, 2026 – Oct 30, 2026
65.4%
Change
-18.7 pts
Short sales a dayon average, of 193.2K shares
90.1K
More than atof 3,666 US-listed companies, same days
37%
Median of alleight in ten from 34.5% to 63.8%
50.4%
  • Oct 13, 2026: Short sales 67.5%
  • Oct 14, 2026: Short sales 60.7%
  • Oct 15, 2026: Short sales 62.4%
  • Oct 16, 2026: Short sales 69.6%
  • Oct 19, 2026: Short sales 79.5%
  • Oct 20, 2026: Short sales 74.1%
  • Oct 21, 2026: Short sales 80%
  • Oct 22, 2026: Short sales 73.9%
  • Oct 23, 2026: Short sales 70%
  • Oct 26, 2026: Short sales 59.1%
  • Oct 27, 2026: Short sales 42.8%
  • Oct 28, 2026: Short sales 47.4%
  • Oct 29, 2026: Short sales 61.8%
  • Oct 30, 2026: Short sales 68.2%
  • Nov 2, 2026: Short sales 56.9%
  • Nov 3, 2026: Short sales 35.6%
  • Nov 4, 2026: Short sales 39.4%
  • Nov 5, 2026: Short sales 42%
  • Nov 6, 2026: Short sales 57.6%
  • Nov 9, 2026: Short sales 54.2%
  • Nov 10, 2026: Short sales 49.2%
  • Nov 11, 2026: Short sales 58.1%
  • Nov 12, 2026: Short sales 46.3%
  • Nov 13, 2026: Short sales 44%
  • Nov 16, 2026: Short sales 50.3%
  • Nov 17, 2026: Short sales 44.2%
  • Nov 18, 2026: Short sales 44.2%
  • Nov 19, 2026: Short sales 44.7%

This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half. Shares held short, which are published twice a month, are not included here.

The ETFs that hold it

Which of the 345 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.

49 ETFs holding it2.53% The largest weight (XMHQ)
  • XMHQInvesco S&P MidCap Quality ETF
    Weight in the fund2.53%
  • IBBiShares Biotechnology ETF
    Weight in the fund1.73%
  • IJKiShares S&P Mid-Cap 400 Growth ETF
    Weight in the fund1.22%
  • XBIState Street(R) SPDR(R) S&P(R) Biotech ETF
    Weight in the fund0.92%
  • LABUDirexion Daily S&P Biotech Bull 3X Shares
    Weight in the fund0.65%
  • SPMDState Street(R) SPDR(R) Portfolio S&P 400(TM) Mid Cap ETF
    Weight in the fund0.63%
  • IJHiShares Core S&P Mid-Cap ETF
    Weight in the fund0.63%
  • MDYState Street SPDR S&P MidCap 400SM ETF Trust
    Weight in the fund0.63%
  • SCHMSchwab U.S. Mid-Cap ETF
    Weight in the fund0.40%
  • IYHiShares U.S. Healthcare ETF
    Weight in the fund0.35%

49 of the 345 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.

Institutional investors by quarter

Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.

880 Managers, Q2 2026$22.7B Value of their positions
  • Q3 2025: Managers 710
  • Q4 2025: Managers 837
  • Q1 2026: Managers 857
  • Q2 2026: Managers 880

Institutional investors by quarter

The fund managers holding UTHR, quarter by quarter, from Q1 2013 to Q2 2025, 50 more quarters

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 12 quarters.

Q2 2026: 880 managers held 41.79M shares, worth $22.7B. During the quarter 106 opened a position, 83 closed one, 316 added and 326 trimmed.

The largest holders, Q2 2026

  • BlackRock
    In the quarter-1.9%
  • Avoro Capital Advisors
    In the quarter+5.6%
  • Vanguard Portfolio Management
    In the quarter-4.2%
  • Vanguard Capital Management
    In the quarter-2.0%
  • State Street
    In the quarter+2.9%
  • Renaissance Technologies
    In the quarter-4.4%
  • Wellington Management Group
    In the quarter-39%
  • Geode Capital Management
    In the quarter-19%
  • Jupiter Topco
    In the quarter
  • Norges Bank
    In the quarter+15%

From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.

Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.

The full analysis

What do United Therapeutics's filings show?

Who buys and sells is one part of United Therapeutics's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about UTHR's shareholders

Didn't find what you were looking for?

Ask us
Which well-known managers hold UTHR?

6 of the managers we track held the shares on Sep 30, 2026. The largest position was Renaissance Technologies's, worth $908M.

Is every insider transaction a purchase or a sale?

No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.